Published in Hepatology on June 01, 2008
Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat (2008) 1.85
KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol (2016) 1.15
KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol (2014) 0.99
The optimal dose of ribavirin for chronic hepatitis C: From literature evidence to clinical practice: The optimal dose of ribavirin for chronic hepatitis C. Hepat Mon (2011) 0.83
Is pegylated interferon superior to interferon, with ribavarin, in chronic hepatitis C genotypes 2/3? World J Gastroenterol (2008) 0.83
Influence of IL28B polymorphisms on response to a lower-than-standard dose peg-IFN-α 2a for genotype 3 chronic hepatitis C in HIV-coinfected patients. PLoS One (2012) 0.79
Meta-analysis: mortality and serious adverse events of peginterferon plus ribavirin therapy for chronic hepatitis C. J Gastroenterol (2012) 0.79
Ultra-rapid virological response, young age, low γ-GT/ALT-ratio, and absence of steatosis identify a subgroup of HCV Genotype 3 patients who achieve SVR with IFN-α(2a) monotherapy. Dig Dis Sci (2011) 0.79
Differences in HCV viral decline between low and standard-dose pegylated-interferon-alpha-2a with ribavirin in HIV/HCV genotype 3 patients. PLoS One (2012) 0.75
Shortening of treatment duration in patients with chronic hepatitis C genotype 2 and 3 - impact of ribavirin dose - a randomized multicentre trial. BMC Res Notes (2011) 0.75
A crossing in therapy for hepatitis C virus genotype 2 or 3: increasing ribavirin dose with shortened duration or reducing ribavirin dose with standard duration. Hepatology (2009) 0.75
Antiviral treatment of chronic hepatitis C in clinical routine. Wien Klin Wochenschr (2010) 0.75
Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology (2008) 6.35
Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med (2010) 3.84
A biopsychosocial model of interferon-alpha-induced depression in patients with chronic hepatitis C infection. Psychother Psychosom (2013) 2.74
Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology (2008) 2.62
Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology (2003) 2.54
Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist (2009) 2.23
Molecular characterization of a non-Babesia divergens organism causing zoonotic babesiosis in Europe. Emerg Infect Dis (2003) 2.12
The Mammalian target of rapamycin pathway regulates nutrient-sensitive glucose uptake in man. Diabetes (2007) 2.09
The role of liver biopsy in the diagnosis and prognosis of patients with acute deterioration of alcoholic cirrhosis. J Hepatol (2011) 2.05
Effect of gender and ITPA polymorphisms on ribavirin-induced anemia in chronic hepatitis C patients. J Hepatol (2013) 2.04
Screening for mutations related to atovaquone/proguanil resistance in treatment failures and other imported isolates of Plasmodium falciparum in Europe. J Infect Dis (2004) 1.99
Impaired circadian rhythm of melatonin secretion in sedated critically ill patients with severe sepsis. Crit Care Med (2002) 1.96
Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology (2008) 1.81
Treatment of opioid-dependent pregnant women: clinical and research issues. J Subst Abuse Treat (2008) 1.77
Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C. Clin Gastroenterol Hepatol (2010) 1.73
Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection. Clin Gastroenterol Hepatol (2011) 1.70
Comparative study of the effectiveness of slow-release morphine and methadone for opioid maintenance therapy. Addiction (2005) 1.57
Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirin. Hepatology (2011) 1.55
Early prediction of hepatitis C virus (HCV) infection relapse in nonresponders to primary interferon therapy by means of HCV RNA whole-blood analysis. Clin Infect Dis (2004) 1.52
Assessment of pulmonary arterial pressure during exercise in collagen vascular disease: echocardiography vs right-sided heart catheterization. Chest (2010) 1.52
Treating pregnant women dependent on opioids is not the same as treating pregnancy and opioid dependence: a knowledge synthesis for better treatment for women and neonates. Addiction (2008) 1.51
A mimic of sarcoidosis. Lancet (2007) 1.49
Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib. Radiology (2012) 1.45
Intrauterine abstinence syndrome (IAS) during buprenorphine inductions and methadone tapers: can we assure the safety of the fetus? J Matern Fetal Neonatal Med (2012) 1.43
Retreatment of patients with chronic hepatitis C not responding to interferon/ribavirin combination therapy with daily interferon plus ribavirin plus amantadine. Wien Klin Wochenschr (2004) 1.42
Use of buprenorphine in pregnancy: patient management and effects on the neonate. Drug Alcohol Depend (2003) 1.36
Successful outcome after intravenous gasoline injection. J Med Toxicol (2007) 1.35
Management of neonatal abstinence syndrome in neonates born to opioid maintained women. Drug Alcohol Depend (2006) 1.31
Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection. Gastroenterology (2011) 1.30
Subclinical impairment of brain function in chronic hepatitis C infection. J Hepatol (2002) 1.28
Acute encephalopathy associated with influenza A virus infection. Clin Infect Dis (2003) 1.25
Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review. Addiction (2012) 1.25
Pathways underlying iron accumulation in human nonalcoholic fatty liver disease. Am J Clin Nutr (2008) 1.25
Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma. Int J Cancer (2013) 1.23
Endoscopic radiofrequency ablation for malignant biliary obstruction: a nationwide retrospective study of 84 consecutive applications. Surg Endosc (2013) 1.17
Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a. Am J Gastroenterol (2002) 1.17
Diagnostic value of quantitative hepatic copper determination in patients with Wilson's Disease. Clin Gastroenterol Hepatol (2005) 1.17
A Comparison of Buprenorphine + Naloxone to Buprenorphine and Methadone in the Treatment of Opioid Dependence during Pregnancy: Maternal and Neonatal Outcomes. Subst Abuse (2013) 1.16
Sudden hearing loss in patients with chronic hepatitis C treated with pegylated interferon/ribavirin. Am J Gastroenterol (2004) 1.16
A role for low hepatic copper concentrations in nonalcoholic Fatty liver disease. Am J Gastroenterol (2010) 1.15
Anxiety as a predictor of relapse in detoxified alcohol-dependent patients. Alcohol Alcohol (2002) 1.14
Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha. Gastroenterology (2002) 1.14
Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells. Mol Cancer (2012) 1.14
Unintended pregnancy in opioid-abusing women. J Subst Abuse Treat (2010) 1.14
Maternal Opioid Treatment: Human Experimental Research (MOTHER)--approach, issues and lessons learned. Addiction (2012) 1.13
Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin. J Hepatol (2011) 1.12
Neonatal outcome following buprenorphine maintenance during conception and throughout pregnancy. Addiction (2003) 1.11
Cocaine use in Europe - a multi-centre study. Methodology and prevalence estimates. Eur Addict Res (2004) 1.10
Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma. Int J Cancer (2013) 1.09
Association between prenatal tobacco exposure and outcome of neonates born to opioid-maintained mothers. Implications for treatment. Eur Addict Res (2009) 1.07
Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response. Gastroenterology (2009) 1.05